ProMIS Neurosciences Inc PMN

PMN update- 2020 in review

[Gbathat]

https://promisneurosciences.com/news/year-in-review-looking-forward-to-2021/

Here is the 2020 review from PMN's Dr. Goldstein.  It provides a good overview on the status of current programs.  It also has some new analysis on aducanumab, still leaning towards approval.

It mentions external challenges with regard to PMN310 capital raise.  Not having any optics on who they are targeting, it is hard for me to assess the validity of these statements.  Obviously COVID has been disruptive with regard to prioritization in pharma.  Maybe some of the companies with large COVID revenues and lots of cash already on hand (i.e. Pfizer) would be a good target.

They have mentioned that $10M is the ask for PHI support.  But it is worth contemplating that PHII and PHIII are likely much more costly, so at the end of the day, it's not just an ask for $10M (from a corporate partner/investor planning perspective).

[Actuarial]

Finally, they have a budget at $10M to support PHI. At the current $25M market cap, that means at least 28.6% = $10M / ($10M + $25M) needs to go with new investors. Anyone want to invest into PMN?

[M101]

Funny, looking through the year's news releases I don't see a header "Lab shut down for Covid19". Maybe that one got lost along with "...executive compensation unaffected."  

[Speyeder999]

Lol.... I got a little excited after all this wait to finally see an update of the company's progress and after going over it a few times, I'm not exactly getting that warm and fuzzy feeling either.   So in a nutshell, advancement on the COVID front, maybe we get results in the first 6 months,  and as for the rest, we have to wait another 12-24 months.   

[M101]

At least Elliot is being consistent. I mean the only other reason he can't raise cash short of a half-price sale is because of Biogen's "mistake".  "The negative advisory committee vote will most likely impact the AD field for some time in 2021, including the very challenging capital formation environment that we and others have faced in this field since Biogen’s

[Gbathat]

I don't doubt that this certainly caused issues, but based on the Alzforum autopsy comments and BAN2401 results, it seems like the amyloid beta hypothesis is good to go. I am still optimistic about a deal given the market opportunity and the cash piling up out there in big pharma.  Sounds like it will take some time though. I am still suspicious that we are waiting on Biogen for some

[retiredcop]

Like I mentioned before...what does the fda do if the treatment is given the green light in Japan or Europe or both....does the fda wait too see what happens overseas or do they taken the  lead and say no to Biogen right now and deal with the questions later ...or do they approve with conditions and save some headaches later. I can't  seem to find the names of the people on that last

[M101]

Whereas an actual year end review would include: We weren't told what was actually going on (lab closure) this year because we can't handle the truth. We won't be told what's going on next year because we must respect our JV partner's privacy.  We can't have executive compensation itemized in the quarterlies because it's an embarrassment that would only drive

[retiredcop]

I am missing something...which lab closed ?

[Gbathat]

one of Dr. Cashman's labs on campus, I believe, per the 2020 review letter published this morning.  It sounds like it was temporary for COVID. 3 months.

[Gbathat]

Giving this PR one more read, and still being confounded by the allusion to 'external challenges' for PMN310, I do believe that their pivoting to the vaccine development is a very good move at this point.

[mrthehorse]

Seems to me like big things were 12-24 months away, 12-24 months ago.  Not bashing, just frustrated.